Aryl hydrocarbon receptor antagonist stemregenin 1 promotes the expansion of human promyelocytic leukemia cell line, NB4

Ryohei Koide, Kasem Kulkeaw, Yuka Tanaka, Anthony Swain, Yoichi Nakanishi, Daisuke Sugiyama

Research output: Contribution to journalArticle

Abstract

Background/Aim: StemRegenin 1 (SR1), an antagonist of aryl hydrocarbon receptor (AHR), reportedly promotes expansion of hematopoietic stem cells but its effect on leukemia cells is unclear. This study focused on the role of SR1 in leukemia cell proliferation. Materials and Methods: AHR expression was compared in the cell lines Jurkat, Kasumi-1, NB4 and K562, using real-time polymerase chain reaction. Highly AHR-expressing NB4 cells were cultured with SR1 for 2 and 4 days, and evaluated for viability and gene expression. DNA microarray was also performed. Results: The viability of NB4 cells treated with 1.5 M SR1 increased at day 4. Expression of B-cell CLL/lymphoma 2 (BCL2) was up-regulated, while that of BCL2 associated X protein (BAX) was down-regulated at day 2. Increased cyclin D1 (CCND1), CCND2 and v-myc avian myelocytomatosis viral oncogene homolog (MYC) expressions were observed at day 4. Global gene expression profiles showed upregulation of splice variant-related genes and downregulation of inflammation-related genes. Conclusion: SR1 promotes the expansion of NB4 cells in vitro, implying the need for caution regarding in vivo use of R1.

Original languageEnglish
Pages (from-to)3635-3643
Number of pages9
JournalAnticancer Research
Volume36
Issue number7
Publication statusPublished - Jan 1 2016

Fingerprint

Aryl Hydrocarbon Receptors
Leukemia
Cell Line
B-Cell Lymphoma
Cyclin D1
Hematopoietic Stem Cells
Oligonucleotide Array Sequence Analysis
Oncogenes
Transcriptome
Genes
Real-Time Polymerase Chain Reaction
Cultured Cells
Cell Survival
Up-Regulation
Down-Regulation
Cell Proliferation
StemRegenin 1
Inflammation
Gene Expression
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Aryl hydrocarbon receptor antagonist stemregenin 1 promotes the expansion of human promyelocytic leukemia cell line, NB4. / Koide, Ryohei; Kulkeaw, Kasem; Tanaka, Yuka; Swain, Anthony; Nakanishi, Yoichi; Sugiyama, Daisuke.

In: Anticancer Research, Vol. 36, No. 7, 01.01.2016, p. 3635-3643.

Research output: Contribution to journalArticle

Koide, Ryohei ; Kulkeaw, Kasem ; Tanaka, Yuka ; Swain, Anthony ; Nakanishi, Yoichi ; Sugiyama, Daisuke. / Aryl hydrocarbon receptor antagonist stemregenin 1 promotes the expansion of human promyelocytic leukemia cell line, NB4. In: Anticancer Research. 2016 ; Vol. 36, No. 7. pp. 3635-3643.
@article{5cde5a1966cf492fb49400a638d00b0b,
title = "Aryl hydrocarbon receptor antagonist stemregenin 1 promotes the expansion of human promyelocytic leukemia cell line, NB4",
abstract = "Background/Aim: StemRegenin 1 (SR1), an antagonist of aryl hydrocarbon receptor (AHR), reportedly promotes expansion of hematopoietic stem cells but its effect on leukemia cells is unclear. This study focused on the role of SR1 in leukemia cell proliferation. Materials and Methods: AHR expression was compared in the cell lines Jurkat, Kasumi-1, NB4 and K562, using real-time polymerase chain reaction. Highly AHR-expressing NB4 cells were cultured with SR1 for 2 and 4 days, and evaluated for viability and gene expression. DNA microarray was also performed. Results: The viability of NB4 cells treated with 1.5 M SR1 increased at day 4. Expression of B-cell CLL/lymphoma 2 (BCL2) was up-regulated, while that of BCL2 associated X protein (BAX) was down-regulated at day 2. Increased cyclin D1 (CCND1), CCND2 and v-myc avian myelocytomatosis viral oncogene homolog (MYC) expressions were observed at day 4. Global gene expression profiles showed upregulation of splice variant-related genes and downregulation of inflammation-related genes. Conclusion: SR1 promotes the expansion of NB4 cells in vitro, implying the need for caution regarding in vivo use of R1.",
author = "Ryohei Koide and Kasem Kulkeaw and Yuka Tanaka and Anthony Swain and Yoichi Nakanishi and Daisuke Sugiyama",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "36",
pages = "3635--3643",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Aryl hydrocarbon receptor antagonist stemregenin 1 promotes the expansion of human promyelocytic leukemia cell line, NB4

AU - Koide, Ryohei

AU - Kulkeaw, Kasem

AU - Tanaka, Yuka

AU - Swain, Anthony

AU - Nakanishi, Yoichi

AU - Sugiyama, Daisuke

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background/Aim: StemRegenin 1 (SR1), an antagonist of aryl hydrocarbon receptor (AHR), reportedly promotes expansion of hematopoietic stem cells but its effect on leukemia cells is unclear. This study focused on the role of SR1 in leukemia cell proliferation. Materials and Methods: AHR expression was compared in the cell lines Jurkat, Kasumi-1, NB4 and K562, using real-time polymerase chain reaction. Highly AHR-expressing NB4 cells were cultured with SR1 for 2 and 4 days, and evaluated for viability and gene expression. DNA microarray was also performed. Results: The viability of NB4 cells treated with 1.5 M SR1 increased at day 4. Expression of B-cell CLL/lymphoma 2 (BCL2) was up-regulated, while that of BCL2 associated X protein (BAX) was down-regulated at day 2. Increased cyclin D1 (CCND1), CCND2 and v-myc avian myelocytomatosis viral oncogene homolog (MYC) expressions were observed at day 4. Global gene expression profiles showed upregulation of splice variant-related genes and downregulation of inflammation-related genes. Conclusion: SR1 promotes the expansion of NB4 cells in vitro, implying the need for caution regarding in vivo use of R1.

AB - Background/Aim: StemRegenin 1 (SR1), an antagonist of aryl hydrocarbon receptor (AHR), reportedly promotes expansion of hematopoietic stem cells but its effect on leukemia cells is unclear. This study focused on the role of SR1 in leukemia cell proliferation. Materials and Methods: AHR expression was compared in the cell lines Jurkat, Kasumi-1, NB4 and K562, using real-time polymerase chain reaction. Highly AHR-expressing NB4 cells were cultured with SR1 for 2 and 4 days, and evaluated for viability and gene expression. DNA microarray was also performed. Results: The viability of NB4 cells treated with 1.5 M SR1 increased at day 4. Expression of B-cell CLL/lymphoma 2 (BCL2) was up-regulated, while that of BCL2 associated X protein (BAX) was down-regulated at day 2. Increased cyclin D1 (CCND1), CCND2 and v-myc avian myelocytomatosis viral oncogene homolog (MYC) expressions were observed at day 4. Global gene expression profiles showed upregulation of splice variant-related genes and downregulation of inflammation-related genes. Conclusion: SR1 promotes the expansion of NB4 cells in vitro, implying the need for caution regarding in vivo use of R1.

UR - http://www.scopus.com/inward/record.url?scp=84992111571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992111571&partnerID=8YFLogxK

M3 - Article

C2 - 27354634

AN - SCOPUS:84992111571

VL - 36

SP - 3635

EP - 3643

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -